Shares of EXACT Sciences Co. (NASDAQ:EXAS) gapped down before the market opened on Tuesday . The stock had previously closed at $67.50, but opened at $68.25. EXACT Sciences shares last traded at $69.28, with a volume of 47945 shares.

A number of analysts have recently issued reports on EXAS shares. BidaskClub downgraded shares of EXACT Sciences from a “hold” rating to a “sell” rating in a report on Friday, August 10th. UBS Group set a $100.00 price target on shares of EXACT Sciences and gave the stock a “buy” rating in a report on Tuesday, October 30th. Leerink Swann restated an “outperform” rating and set a $76.00 price target (up previously from $67.00) on shares of EXACT Sciences in a report on Wednesday, July 18th. Jefferies Financial Group cut their price target on shares of EXACT Sciences from $60.00 to $57.00 and set a “buy” rating for the company in a report on Thursday, August 2nd. Finally, Robert W. Baird raised their price target on shares of EXACT Sciences from $65.00 to $74.00 and gave the stock an “outperform” rating in a report on Thursday, August 23rd. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. EXACT Sciences currently has a consensus rating of “Buy” and an average price target of $84.08.

The company has a debt-to-equity ratio of 0.94, a quick ratio of 11.72 and a current ratio of 12.08. The firm has a market cap of $9.17 billion, a price-to-earnings ratio of -70.11 and a beta of 1.21.

EXACT Sciences (NASDAQ:EXAS) last posted its earnings results on Tuesday, October 30th. The medical research company reported ($0.37) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.42) by $0.05. EXACT Sciences had a negative net margin of 35.83% and a negative return on equity of 20.18%. The firm had revenue of $118.29 million during the quarter, compared to the consensus estimate of $109.33 million. During the same quarter last year, the firm earned ($0.23) EPS. The firm’s revenue for the quarter was up 63.0% on a year-over-year basis. As a group, research analysts expect that EXACT Sciences Co. will post -1.53 earnings per share for the current year.

In other EXACT Sciences news, Director Michael S. Wyzga sold 2,468 shares of the firm’s stock in a transaction that occurred on Tuesday, August 28th. The shares were sold at an average price of $74.85, for a total value of $184,729.80. Following the completion of the transaction, the director now owns 9,112 shares of the company’s stock, valued at approximately $682,033.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Graham Peter Lidgard sold 37,613 shares of the firm’s stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $75.01, for a total transaction of $2,821,351.13. Following the completion of the transaction, the insider now directly owns 29,398 shares of the company’s stock, valued at approximately $2,205,143.98. The disclosure for this sale can be found here. Insiders sold a total of 218,255 shares of company stock valued at $15,791,740 in the last quarter. 3.20% of the stock is owned by insiders.

A number of hedge funds have recently modified their holdings of the business. William Blair Investment Management LLC boosted its position in EXACT Sciences by 28.7% in the 3rd quarter. William Blair Investment Management LLC now owns 2,334,045 shares of the medical research company’s stock valued at $184,203,000 after buying an additional 520,579 shares during the period. Zevenbergen Capital Investments LLC boosted its position in EXACT Sciences by 1.8% in the 2nd quarter. Zevenbergen Capital Investments LLC now owns 2,070,170 shares of the medical research company’s stock valued at $123,775,000 after buying an additional 35,725 shares during the period. Artisan Partners Limited Partnership boosted its position in EXACT Sciences by 25.8% in the 2nd quarter. Artisan Partners Limited Partnership now owns 1,879,525 shares of the medical research company’s stock valued at $112,377,000 after buying an additional 385,766 shares during the period. Frontier Capital Management Co. LLC boosted its position in EXACT Sciences by 37.7% in the 3rd quarter. Frontier Capital Management Co. LLC now owns 1,585,851 shares of the medical research company’s stock valued at $125,155,000 after buying an additional 434,184 shares during the period. Finally, Eagle Asset Management Inc. boosted its position in EXACT Sciences by 46.3% in the 3rd quarter. Eagle Asset Management Inc. now owns 1,227,683 shares of the medical research company’s stock valued at $96,888,000 after buying an additional 388,434 shares during the period. 87.58% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “EXACT Sciences (EXAS) Shares Gap Down to $68.25” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/11/13/exact-sciences-exas-shares-gap-down-to-68-25.html.

EXACT Sciences Company Profile (NASDAQ:EXAS)

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

See Also: How are institutional investors different from individual investors?

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.